Cuprina Holdings (Cayman) Limited revenue by segment CUPR
Cuprina Holdings (Cayman) Limited splits its revenue into 2 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Maggot Debridement Therapy Product at $34,365, 89% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
|---|---|---|
| Revenue |
0
|
0
|
| Maggot Debridement Therapy Product |
0
share 88.6%
|
—
|
| Cosmeceutical Product |
0
share 11.4%
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. More on our methodology.
Company profile
- Industry
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (SIC 3842)
- Listed as
- CUPR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Singapore, Singapore
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1995704
Other Orthopedic, Prosthetic & Surgical Appliances & Supplies companies
- Intuitive Surgical Inc ISRG
- Edwards Lifesciences Corp EW
- STERIS plc STE
- Zimmer Biomet Holdings, Inc. ZBH
- Smith & Nephew PLC SNN
- Align Technology Inc ALGN
- MSA Safety Inc MSA
- Establishment Labs Holdings Inc. ESTA
All 29 Orthopedic, Prosthetic & Surgical Appliances & Supplies companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.